Ameritas Investment Partners Inc. raised its holdings in Blueprint Medicines Corporation (NASDAQ:BPMC) by 68.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,410 shares of the biotechnology company’s stock after purchasing an additional 1,391 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Blueprint Medicines Corporation were worth $173,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of BPMC. BlackRock Inc. increased its stake in Blueprint Medicines Corporation by 39.6% in the second quarter. BlackRock Inc. now owns 2,864,255 shares of the biotechnology company’s stock valued at $145,131,000 after purchasing an additional 811,820 shares during the period. State Street Corp increased its stake in Blueprint Medicines Corporation by 76.8% in the second quarter. State Street Corp now owns 1,400,035 shares of the biotechnology company’s stock valued at $70,936,000 after purchasing an additional 608,296 shares during the period. TimesSquare Capital Management LLC acquired a new position in Blueprint Medicines Corporation in the second quarter valued at $28,375,000. FMR LLC increased its stake in Blueprint Medicines Corporation by 10.8% in the second quarter. FMR LLC now owns 5,300,589 shares of the biotechnology company’s stock valued at $268,581,000 after purchasing an additional 516,835 shares during the period. Finally, Vanguard Group Inc. increased its stake in Blueprint Medicines Corporation by 34.5% in the first quarter. Vanguard Group Inc. now owns 1,220,446 shares of the biotechnology company’s stock valued at $48,806,000 after purchasing an additional 313,181 shares during the period. Institutional investors own 90.64% of the company’s stock.

In related news, CEO Jeffrey W. Albers sold 30,000 shares of the stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $49.62, for a total value of $1,488,600.00. Following the sale, the chief executive officer now owns 18,272 shares of the company’s stock, valued at approximately $906,656.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $49.08, for a total transaction of $981,600.00. Following the completion of the sale, the chief executive officer now directly owns 18,272 shares in the company, valued at approximately $896,789.76. The disclosure for this sale can be found here. Insiders have sold 69,305 shares of company stock worth $3,606,782 over the last three months. 3.40% of the stock is owned by corporate insiders.

A number of research analysts have commented on BPMC shares. DA Davidson started coverage on shares of Blueprint Medicines Corporation in a research note on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective on the stock. Zacks Investment Research lowered shares of Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Canaccord Genuity lifted their price objective on shares of Blueprint Medicines Corporation from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, September 20th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $79.00 price objective (up from $64.00) on shares of Blueprint Medicines Corporation in a research note on Wednesday, September 20th. Finally, BTIG Research started coverage on shares of Blueprint Medicines Corporation in a research note on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $68.69.

Blueprint Medicines Corporation (NASDAQ:BPMC) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.06). The business had revenue of $8.07 million for the quarter, compared to analyst estimates of $5.35 million. Blueprint Medicines Corporation had a negative return on equity of 43.11% and a negative net margin of 437.83%. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. During the same period last year, the company posted ($0.62) earnings per share.

COPYRIGHT VIOLATION WARNING: “Ameritas Investment Partners Inc. Acquires 1,391 Shares of Blueprint Medicines Corporation (BPMC)” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/ameritas-investment-partners-inc-acquires-1391-shares-of-blueprint-medicines-corporation-bpmc/1675166.html.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corporation (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.